Immunotherapy and radiation combo tested for rare chest cancer
NCT ID NCT04166734
First seen Feb 04, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This early-stage trial tested whether combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) could help people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The study aimed to check safety and side effects in patients whose cancer had worsened after standard chemotherapy. Only 5 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Royal Marsden NHS Foundation Trust
Chelsea, United Kingdom
Conditions
Explore the condition pages connected to this study.